Qualify For a Study or Trial

This study is a phase 2a clinical trial testing the safety, tolerability, and efficacy of the investigational medication KAN-101. 

KAN-101 targets the immune cells that drive celiac disease and leaves the otherwise healthy components of the immune system intact. KAN-101 acts by re-educating T cells, or tolerizing them, so they do not respond to gluten antigens.  

This trial may be an option for you if you: 

• Are 18-70 years old 
• Have biopsy-confirmed celiac disease 
• Currently follow a gluten-free diet 

Learn more at Anokion.com/SynCeD.

This study is a phase 1b/2 clinical trial testing the safety and tolerability of the investigational medication KAN-101.

KAN-101 targets the immune cells that drive celiac disease and leaves the otherwise healthy components of the immune system intact. KAN-101 acts by re-educating T cells, or tolerizing them, so they do not respond to gluten antigens.

Requirements:

• 18-70 years
• Biopsy-confirmed celiac disease
• On a gluten-free diet for at least the last 12 months

Learn more at Anokion.com/ACeD-it.

This phase 1 clinical study is evaluating the safety of the study medication, DONQ52.

This medication is designed to target an immune complex known to cause celiac disease symptoms. This may protect the small intestine of a person with celiac disease.

There is no gluten challenge in this study. You may be compensated for time and travel.

Requirements:

• You are 18-70 years old
• You have celiac disease
• You are already on a gluten-free diet for at least 12 months
• Have or can obtain medical records which show diagnosis of celiac disease
• Other requirements will apply.

If you’re interested in the study, think you may qualify, or want to find a study site location near you, visit www.celiacdiseasestudy.com.

Now enrolling adults with celiac disease to participate in a research study investigating TEV-53408 for the treatment of celiac disease.   

TEV-53408 is an investigational antibody designed to block interleukin-15 with the goal of preventing intestinal damage and symptoms that occur when people with celiac disease ingest gluten.      

Compensation for time and travel may be available.  

 Requirements:  

• 18-70 years old  
• Biopsy-confirmed celiac disease  
• On a gluten-free diet 

 Learn more at tevstudy.celiac.org.

The ILLUMINATE-062 Study is a phase 2 clinical research study evaluating the safety and effectiveness of an investigational drug designed to break down gluten in the stomach and improve control of celiac disease for people on a gluten-free diet. If you periodically experience celiac-related gastrointestinal symptoms, despite your best efforts to follow a gluten-free diet, this study may be a good fit for you.

In order to qualify, one must:

• Be 18 years old or older
• Have biopsy-confirmed celiac disease
• Have been on a gluten-free diet for at least the past 12 months

Some study visits can be completed at home, and all study-related care will be provided at no cost. Participants may be compensated for time + travel.

To learn more, please visit: illuminatecd-cdf2.com.